The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases
- 6 March 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 39 (4), 1-2
- https://doi.org/10.1007/s40273-021-01007-8
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”PharmacoEconomics, 2021
- Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics, 2020
- Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut SyndromePharmacoEconomics, 2020
- Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility AnalysisPharmacoEconomics, 2020
- Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in CanadaCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2019
- Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic EvaluationsPharmacoEconomics, 2019
- PRO58 QUALITY OF LIFE IN PATIENTS WITH DRAVET SYNDROME OR LENNOX GASTAUT SYNDROME IN THE UK: HIGHER SEIZURE FREQUENCY HAS A SUBSTANTIAL NEGATIVE IMPACT ON QUALITY OF LIFEValue in Health, 2019
- Quality Traits of “Cannabidiol Oils”: Cannabinoids Content, Terpene Fingerprint and Oxidation Stability of European Commercially Available PreparationsMolecules, 2018
- The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare DiseasesMedical Decision Making, 2014